Pricing Log in Create free account

Acumen Pharmaceuticals, Inc. (ABOS) vs Outlook Therapeutics, Inc. (OTLK)

Acumen Pharmaceuticals, Inc. and Outlook Therapeutics, Inc. are both Biotechnology companies. Acumen Pharmaceuticals, Inc. and Outlook Therapeutics, Inc. are of similar size ($121.7M and $120.8M). Outlook Therapeutics, Inc. has the higher net margin (5,253.4% vs 0.00%) and the higher return on invested capital (0.00% vs 0.00%). Across the 13 metrics below, Outlook Therapeutics, Inc. leads on 9 and Acumen Pharmaceuticals, Inc. on 4.

Valuation

Metric ABOS OTLK Biotechnology median
P/E n/m n/m 8.50
P/S 85.03 n/m 9.71
P/B 2.13 n/m 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 30.28 (73.15) 9.21
Earnings yield (96.45%) (213.12%) (33.15%)
Free cash flow yield (75.24%) (84.46%) (25.50%)

Profitability

Metric ABOS OTLK Biotechnology median
Gross margin 0.00% 195.62% 65.16%
Operating margin 0.00% 4,781.76% 0.00%
Net margin 0.00% 5,253.40% 0.00%
Free cash flow margin 0.00% 4,826.38% 0.00%
Return on equity (120.50%) 256.92% (56.36%)
Return on assets (72.97%) (251.66%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric ABOS OTLK Biotechnology median
Revenue growth (TTM) — (113.55%) 6.02%
EPS growth (last fiscal year) (16.96%) 55.81% 30.26%
Revenue growth, 5-year CAGR — (22.99%) 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ABOS OTLK Biotechnology median
Debt to equity 0.55 (1.75) 0.00
Current ratio 2.47 0.81 4.72
Net debt to EBITDA 0.69 (0.33) 0.96

Dividend

Metric ABOS OTLK Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric ABOS OTLK Biotechnology median
Market cap 120.77m 121.72m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack